

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 1 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

**IMPORTANT REMINDER**

This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted standards of medical practice, peer-reviewed medical literature, government agency/program approval status, and other indicia of medical necessity.

The purpose of this Clinical Policy is to provide a guide to medical necessity. Benefit determinations should be based in all cases on the applicable contract provisions governing plan benefits (“Benefit Plan Contract”) and applicable state and federal requirements including Local Coverage Determinations (LCDs), as well as applicable plan-level administrative policies and procedures. To the extent there are any conflicts between this Clinical Policy and the Benefit Plan Contract provisions, the Benefit Plan Contract provisions will control.

Clinical policies are intended to be reflective of current scientific research and clinical thinking. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

**SUBJECT:**

Medical necessity determination for performance of fluorescein angiography.

**DESCRIPTION:**

Fluorescein Angiography plays an important role in ophthalmoscopic diagnosis, especially the diagnosis and evaluation of many retinal conditions. Because it can precisely delineate areas of abnormality, it is an essential guide for planning laser treatment of retinal vascular disease. Following the intravascular administration of a contrast solution of sodium fluorescein, a blue light is used to excite the fluorescein which is useful in detecting leaking capillaries (subretinal neovascularization). A permanent record of the study is always made using either photographic or electronic imaging methods. Multiple black and

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 2 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

white photographs of the ocular fundus at different times following fluorescein injection provides much information concerning vascular obstructions, neovascularization, microaneurysms, abnormal capillary permeability and defects of the retinal pigment epithelium.

Normal values of a fluorescein angiogram include normal retinal vessels, retina, and choroidal circulation.

**POLICY/CRITERIA:**

Envolve Vision Benefits, Inc. (Envolve Vision) will consider fluorescein angiography medically indicated for the following conditions:

Initial evaluation of a patient with abnormal findings of the fundus/retina on ophthalmoscopy exam including:

- Choroidal Neovascular Membranes (CNVM)
- Lesions of the Retinal Pigment Epithelium (RPE)
  - Serous Detachment of the RPE
  - Tears of rips of the RPE
  - Hemorrhagic detachment
- Fibrovascular Disciform Scar
- Vitreous Hemorrhage (patient presents with sudden loss of vision)
- Drusen
- Diabetic Retinopathy

Evaluation of patient presenting with symptoms of sudden vision loss (especially central vision), blurred vision, distortion, etc., which may suggest a subretinal neovascularization and abnormal findings of the fundus/retina on ophthalmoscopy exam.

Evaluation of patients with nonproliferative (background) and proliferative diabetic retinopathy without macular edema. Frequency is determined by disease progression and the treatment performed. Fluorescein angiography may be performed on the treated eye only at 6 weeks post-treatment and as often as every 8-12 weeks to assist in management of the retinopathy.

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 3 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

- Background retinopathy is characterized by intraretinal microaneurysms, hemorrhages and hard exudates
- Proliferative retinopathy is characterized by neovascularization arising from the disk or the retinal vessels

Evaluation of patients with chorioretinitis, chorioretinal scars of choroidal degeneration, dystrophies, hemorrhage and rupture or detachment.

Evaluation of patients with known retinal or macular disorders such as:

- Age-related macular degeneration
  - Nonexudative – every 6 to 12 months
  - Exudative
    - 1 to 2 weeks, 1 month, 6 weeks post photocoagulation
    - Then every 6 to 12 months
- Macular edema secondary to diabetic retinopathy
- Cystoid macular edema
- Central retinal vein occlusion
- Branch retinal vein occlusion
- Tumors of the choroid and retina
- Retinal arterial disease

Evaluation of patients with ocular tumors, visual loss in systemic disease and optic disc disease

Documentation requirements:

Fluorescein angiography is covered twice per year (service date to service date) when medically indicated and documented in accordance with this policy. The medical record must clearly indicate the reason for the diagnostic test and how it will aid in clinical decision-making. An interpretation and report must be included as a permanent part of the medical record. When multiple diagnostic tests are performed, a separate interpretation and report must be completed for each test. The interpretation and report may be included with the encounter documentation; however, must be separate from an examination.

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 4 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

The interpretation and report must contain the following:

- Clinical findings – pertinent findings regarding the test results
- Comparative Data – comparison to previous test results (if applicable)
- Clinical Management – how the test results will affect management of the condition/disease
  - Change/increase/stop medication
  - Recommendation for surgery
  - Recommendation for further diagnostic testing
  - Referral to a specialist/sub-specialist for additional treatment

Medical records must be submitted with the claim in order for services that exceed frequency limitations to be considered for payment.

**AUTHORIZATION PROTOCOLS:**

Fluorescein angiography is subject to retrospective medical record review.

Professional services must be provided by duly licensed eye care providers within the scope of licensure as defined by applicable State guidelines.

**SCIENTIFIC BACKGROUND:**

Intravenous Fluorescein angiography (IVFA) or fluorescent angiography is a technique for examining the circulation of the retina and choroid using a fluorescent dye and a specialized camera. It involves injection of sodium fluorescein into the systemic circulation, and then an angiogram is obtained by photographing the fluorescence emitted after illumination of the retina with blue light at a wavelength of 490 nanometers. The test uses the dye tracing method.

- Baseline color and black and white red-free filtered images are taken prior to injection. The black and white images are filtered red-free (a green filter) to increase contrast and often gives a better image of the fundus than the color image.
- A 6 second bolus injection of 2-5cc of sodium fluorescein into a vein in the arm or hand.
- A series of black-and-white or digital photographs are taken of the retina before and after the fluorescein reaches the retinal circulation (approximately

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 5 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

10 seconds after injection). The early images allow for the recognition of autofluorescence of the retinal tissues. Photos are taken approximately once every second for about 20 seconds, then less often. A delayed image is obtained at 5 and 10 minutes. Some doctors like to see a 15 minute image as well.

- A filter is placed in the camera so only the fluorescent, yellow-green light (530 nm) is recorded. The camera may however pick up signals from pseudofluorescence or autofluorescence. In pseudofluorescence, non-fluorescent light is imaged. This occurs when blue light reflected from the retina passes through the filter. This is generally a problem with older filters, and annual replacement of these filters is recommended. In autofluorescence, fluorescence from the eye occurs without injection of the dye. This may be seen with optic nerve head drusen, astrocytic hamartoma, or calcific scarring.
- Black-and-white photos give better contrast than color photos, which aren't necessary since only one color is being transmitted through the filter.

**REFERENCES:**

CGS Administrators, LLC Local Coverage Determination Ophthalmic Angiography (Fluorescein and Indocyanine Green) L34175, Ohio, Revised 10/1/2016

First Coast Service Options, Inc., Local Coverage Determination L33997 Fluorescein Angiography, Puerto Rico, Revised 10/1/2017

Texas Medicaid Provider Procedures Manual, [http://www.tmhp.com/Pages/Medicaid/Medicaid\\_Publications\\_Provider\\_manual.aspx](http://www.tmhp.com/Pages/Medicaid/Medicaid_Publications_Provider_manual.aspx)

OC.UM.CP.0072 Optos® / EasyScan® Retinal Imaging

**CODING IMPLICATIONS:**

The following codes for treatment and procedures are for informational purposes only. They are current at time of review of this policy. Inclusion or exclusion of

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 6 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

any codes does not guarantee coverage. Please refer to your State contract or applicable National and Local Coverage Determination for exact coverage implications.

Envolve Vision follows National Correct Coding Initiative (CCI) guidelines in processing claims for these services. If a claim is denied based upon CCI edits, an appeal must be submitted to Envolve Vision with a letter signed by the provider indicating the necessity of performing multiple services at the same encounter and the medical records clearly stating what additional information will be gleaned and how these multiple images will positively impact the patient's care.

Envolve Vision follows the Multiple Procedure Payment Reduction guidelines (MPPR) when reimbursing for multiple diagnostic procedures. CCI guidelines are applied prior to MPPR.

Procedure 92235 is a bilateral procedure. To file for the complete procedure, append the code with a RT or LT modifier to indicate which eye was tested. CPT code 92235 has both a technical and professional component. To claim only the professional component, append modifier 26. To claim only the technical component, append modifier TC. CPT code 92235 includes any setup, insertion of intravenous line, injection, and cost of dye and the development of the images.

<b>ICD-10 Code</b>	<b>ICD-10 Code Description</b>
A18.53	Tuberculous chorioretinitis
B39.4	Histoplasmosis capsulati unspecified
B39.9	Histoplasmosis, unspecified
B58.01	Toxoplasma chorioretinitis
C69.21	Malignant neoplasm of right retina
C69.22	Malignant neoplasm of left retina
C69.31	Malignant neoplasm of right choroid
C69.32	Malignant neoplasm of left choroid

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 7 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

D31.21	Benign neoplasm of right retina
D31.22	Benign neoplasm of left retina
D31.31	Benign neoplasm of right choroid
D31.32	Benign neoplasm of left choroid
D86.83	Sarcoid iridocyclitis
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 8 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral



**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 9 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 10 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 11 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 12 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 13 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 14 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 15 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 16 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye



**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 17 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 18 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 19 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 20 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

G45.3	Amaurosis fugax
H15.031	Posterior scleritis, right eye
H15.032	Posterior scleritis, left eye
H15.033	Posterior scleritis, bilateral
H16.241	Ophthalmia nodosa, right eye
H16.242	Ophthalmia nodosa, left eye
H16.243	Ophthalmia nodosa, bilateral
H20.821	Vogt-Koyanagi syndrome right eye
H20.822	Vogt-Koyanagi syndrome left eye
H20.823	Vogt-Koyanagi syndrome bilateral
H21.331	Parasitic cyst of iris, ciliary body or anterior chamber right eye
H21.332	Parasitic cyst of iris, ciliary body or anterior chamber left eye
H21.333	Parasitic cyst of iris, ciliary body or anterior chamber bilateral
H30.011	Focal chorioretinal inflammation, juxtapapillary, right eye
H30.012	Focal chorioretinal inflammation, juxtapapillary, left eye
H30.013	Focal chorioretinal inflammation, juxtapapillary, bilateral
H30.021	Focal chorioretinal inflammation of posterior pole, right eye
H30.022	Focal chorioretinal inflammation of posterior pole, left eye
H30.023	Focal chorioretinal inflammation of posterior pole, bilateral
H30.031	Focal chorioretinal inflammation, peripheral, right eye
H30.032	Focal chorioretinal inflammation, peripheral, left eye
H30.033	Focal chorioretinal inflammation, peripheral, bilateral
H30.041	Focal chorioretinal inflammation, macular or paramacular, right eye
H30.042	Focal chorioretinal inflammation, macular or paramacular, left eye
H30.043	Focal chorioretinal inflammation, macular or paramacular, bilateral
H30.111	Disseminated chorioretinal inflammation of posterior pole, right eye
H30.112	Disseminated chorioretinal inflammation of posterior pole, left eye
H30.113	Disseminated chorioretinal inflammation of posterior pole, bilateral
H30.121	Disseminated chorioretinal inflammation, peripheral right eye
H30.122	Disseminated chorioretinal inflammation, peripheral, left eye
H30.123	Disseminated chorioretinal inflammation, peripheral, bilateral
H30.131	Disseminated chorioretinal inflammation, generalized, right eye
H30.132	Disseminated chorioretinal inflammation, generalized, left eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 21 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H30.133	Disseminated chorioretinal inflammation, generalized, bilateral
H30.141	Acute posterior multifocal placoid pigment epitheliopathy, right eye
H30.142	Acute posterior multifocal placoid pigment epitheliopathy, left eye
H30.143	Acute posterior multifocal placoid pigment epitheliopathy, bilateral
H30.21	Posterior cyclitis, right eye
H30.22	Posterior cyclitis, left eye
H30.23	Posterior cyclitis, bilateral
H30.811	Harada's disease, right eye
H30.812	Harada's disease, left eye
H30.813	Harada's disease, bilateral
H31.011	Macula scars of posterior pole (postinflammatory) (post-traumatic) right eye
H31.012	Macula scars of posterior pole (postinflammatory) (post-traumatic) left eye
H31.013	Macula scars of posterior pole (postinflammatory) (post-traumatic) bilateral
H31.021	Solar retinopathy, right eye
H31.022	Solar retinopathy, left eye
H31.023	Solar retinopathy, bilateral
H31.111	Age-related choroidal atrophy, right eye
H31.112	Age-related choroidal atrophy, left eye
H31.113	Age-related choroidal atrophy, bilateral
H31.121	Diffuse secondary atrophy of choroid, right eye
H31.122	Diffuse secondary atrophy of choroid, left eye
H31.123	Diffuse secondary atrophy of choroid, bilateral
H31.21	Choroideremia
H31.22	Choroidal dystrophy (central areolar) (generalized) (peripapillary)
H31.23	Gyrate atrophy, choroid
H31.311	Expulsive choroidal hemorrhage right eye
H31.312	Expulsive choroidal hemorrhage left eye
H31.313	Expulsive choroidal hemorrhage bilateral
H31.321	Choroidal rupture right eye
H31.322	Choroidal rupture left eye
H31.323	Choroidal rupture bilateral

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 22 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H31.411	Hemorrhagic choroidal detachment, right eye
H31.412	Hemorrhagic choroidal detachment, left eye
H31.413	Hemorrhagic choroidal detachment, bilateral
H31.421	Serous choroidal detachment, right eye
H31.422	Serous choroidal detachment, left eye
H31.423	Serous choroidal detachment, bilateral
H33.121	Parasitic cyst of retina right eye
H33.122	Parasitic cyst of retina left eye
H33.123	Parasitic cyst of retina bilateral
H33.21	Serous retinal detachment, right eye
H33.22	Serous retinal detachment, left eye
H33.23	Serous retinal detachment, bilateral
H34.01	Transient retinal artery occlusion, right eye
H34.02	Transient retinal artery occlusion, left eye
H34.03	Transient retinal artery occlusion, bilateral
H34.11	Central retinal artery occlusion, right eye
H34.12	Central retinal artery occlusion, left eye
H34.13	Central retinal artery occlusion, bilateral
H34.211	Partial retinal artery occlusion, right eye
H34.212	Partial retinal artery occlusion, left eye
H34.213	Partial retinal artery occlusion, bilateral
H34.231	Retinal artery branch occlusion, right eye
H34.232	Retinal artery branch occlusion, left eye
H34.233	Retinal artery branch occlusion, bilateral
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 23 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H34.821	Venous engorgement, right eye
H34.822	Venous engorgement, left eye
H34.823	Venous engorgement, bilateral
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.011	Changes in retinal vascular appearance, right eye
H35.012	Changes in retinal vascular appearance, left eye
H35.013	Changes in retinal vascular appearance, bilateral
H35.021	Exudative retinopathy, right eye
H35.022	Exudative retinopathy, left eye
H35.023	Exudative retinopathy, bilateral
H35.031	Hypertensive retinopathy, right eye
H35.032	Hypertensive retinopathy, left eye
H35.033	Hypertensive retinopathy, bilateral
H35.041	Retinal micro-aneurysms, unspecified, right eye
H35.042	Retinal micro-aneurysms, unspecified, left eye
H35.043	Retinal micro-aneurysms, unspecified, bilateral
H35.051	Retinal neovascularization, unspecified, right eye
H35.052	Retinal neovascularization, unspecified, left eye
H35.053	Retinal neovascularization, unspecified, bilateral
H35.061	Retinal vasculitis, right eye
H35.062	Retinal vasculitis, left eye
H35.063	Retinal vasculitis, bilateral

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 24 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H35.071	Retinal telangiectasis, right eye
H35.072	Retinal telangiectasis, left eye
H35.073	Retinal telangiectasis, bilateral
H35.111	Retinopathy of prematurity, stage 0, right eye
H35.112	Retinopathy of prematurity, stage 0, left eye
H35.113	Retinopathy of prematurity, stage 0, bilateral
H35.121	Retinopathy of prematurity, stage 1, right eye
H35.122	Retinopathy of prematurity, stage 1, left eye
H35.123	Retinopathy of prematurity, stage 1, bilateral
H35.131	Retinopathy of prematurity, stage 2, right eye
H35.132	Retinopathy of prematurity, stage 2, left eye
H35.133	Retinopathy of prematurity, stage 2, bilateral
H35.141	Retinopathy of prematurity, stage 3, right eye
H35.142	Retinopathy of prematurity, stage 3, left eye
H35.143	Retinopathy of prematurity, stage 3, bilateral
H35.151	Retinopathy of prematurity, stage 4, right eye
H35.152	Retinopathy of prematurity, stage 4, left eye
H35.153	Retinopathy of prematurity, stage 4, bilateral
H35.161	Retinopathy of prematurity, stage 5, right eye
H35.162	Retinopathy of prematurity, stage 5, left eye
H35.163	Retinopathy of prematurity, stage 5, bilateral
H35.171	Retrolental fibroplasia, right eye
H35.172	Retrolental fibroplasia, left eye
H35.173	Retrolental fibroplasia, bilateral
H35.3111	Nonexudative age-related macular degeneration, right eye, early dry stage
H35.3112	Nonexudative age-related macular degeneration, right eye, intermediate dry stage
H35.3113	Nonexudative age-related macular degeneration, right eye, advanced atrophic without subfoveal involvement
H35.3114	Nonexudative age-related macular degeneration, right eye, advanced atrophic with subfoveal involvement
H35.3121	Nonexudative age-related macular degeneration, left eye, early dry stage



**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 25 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H35.3122	Nonexudative age-related macular degeneration, left eye, intermediate dry stage
H35.3123	Nonexudative age-related macular degeneration, left eye, advanced atrophic without subfoveal involvement
H35.3124	Nonexudative age-related macular degeneration, left eye, advanced atrophic with subfoveal involvement
H35.3131	Nonexudative age-related macular degeneration, bilateral, early dry stage
H35.3132	Nonexudative age-related macular degeneration, bilateral, intermediate dry stage
H35.3133	Nonexudative age-related macular degeneration, bilateral, advanced atrophic without subfoveal involvement
H35.3134	Nonexudative age-related macular degeneration, bilateral, advanced atrophic with subfoveal involvement
H35.3211	Exudative age-related macular degeneration, right eye with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3221	Exudative age-related macular degeneration, left eye with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.33	Angioid streaks of macula
H35.341	Macular cyst, hole, or pseudohole, right eye
H35.342	Macular cyst, hole, or pseudohole, left eye
H35.343	Macular cyst, hole, or pseudohole, bilateral
H35.351	Cystoid macular degeneration, right eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 26 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H35.352	Cystoid macular degeneration, left eye
H35.353	Cystoid macular degeneration, bilateral
H35.371	Puckering of macula, right eye
H35.372	Puckering of macula, left eye
H35.373	Puckering of macula, bilateral
H35.381	Toxic maculopathy, right eye
H35.382	Toxic maculopathy, left eye
H35.383	Toxic maculopathy, bilateral
H35.451	Secondary pigmentary degeneration right eye
H35.452	Secondary pigmentary degeneration left eye
H35.453	Secondary pigmentary degeneration bilateral
H35.461	Secondary vitreoretinal degeneration right eye
H35.462	Secondary vitreoretinal degeneration left eye
H35.463	Secondary vitreoretinal degeneration bilateral
H35.51	Vitreoretinal dystrophy
H35.52	Pigmentary retinal dystrophy
H35.53	Other dystrophies primarily involving the sensory retina
H35.54	Dystrophies primarily involving the retinal pigment epithelium
H35.61	Retinal hemorrhage, right eye
H35.62	Retinal hemorrhage, left eye
H35.63	Retinal hemorrhage, bilateral
H35.711	Central serous chorioretinopathy, right eye
H35.712	Central serous chorioretinopathy, left eye
H35.713	Central serous chorioretinopathy, bilateral
H35.721	Serous detachment of retinal pigment epithelium, right eye
H35.722	Serous detachment of retinal pigment epithelium, left eye
H35.723	Serous detachment of retinal pigment epithelium, bilateral
H35.731	Hemorrhagic detachment of retinal pigment epithelium, right eye
H35.732	Hemorrhagic detachment of retinal pigment epithelium, left eye
H35.733	Hemorrhagic detachment of retinal pigment epithelium, bilateral
H35.81	Retinal edema
H35.82	Retinal ischemia
H43.21	Crystalline deposits in vitreous body right eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 27 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H43.22	Crystalline deposits in vitreous body left eye
H43.23	Crystalline deposits in vitreous body bilateral
H44.011	Panophthalmitis (acute) right eye
H44.012	Panophthalmitis (acute) left eye
H44.013	Panophthalmitis (acute) bilateral
H44.111	Panuveitis right eye
H44.112	Panuveitis left eye
H44.113	Panuveitis bilateral
H44.121	Parasitic endophthalmitis unspecified right eye
H44.122	Parasitic endophthalmitis unspecified left eye
H44.123	Parasitic endophthalmitis unspecified bilateral
H44.131	Sympathetic uveitis right eye
H44.132	Sympathetic uveitis left eye
H44.133	Sympathetic uveitis bilateral
H44.21	Degenerative myopia right eye
H44.22	Degenerative myopia left eye
H44.23	Degenerative myopia bilateral
H44.2A1	Degenerative myopia with choroidal neovascularization, right eye
H44.2A2	Degenerative myopia with choroidal neovascularization, left eye
H44.2A3	Degenerative myopia with choroidal neovascularization, bilateral
H44.2B1	Degenerative myopia with macular hole, right eye
H44.2B2	Degenerative myopia with macular hole, left eye
H44.2B3	Degenerative myopia with macular hole, bilateral
H44.2C1	Degenerative myopia with retinal detachment, right eye
H44.2C2	Degenerative myopia with retinal detachment, left eye
H44.2C3	Degenerative myopia with retinal detachment, bilateral
H44.2D1	Degenerative myopia with foveoschisis, right eye
H44.2D2	Degenerative myopia with foveoschisis, left eye
H44.2D3	Degenerative myopia with foveoschisis, bilateral
H44.2E1	Degenerative myopia with other maculopathy, right eye
H44.2E2	Degenerative myopia with other maculopathy, left eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 28 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H44.2E3	Degenerative myopia with other maculopathy, bilateral
H44.311	Chalcosis right eye
H44.312	Chalcosis left eye
H44.313	Chalcosis bilateral
H44.321	Siderosis of eye right eye
H44.322	Siderosis of eye left eye
H44.323	Siderosis of eye bilateral
H44.641	Retained (old) magnetic foreign body in lens right eye
H44.642	Retained (old) magnetic foreign body in lens left eye
H44.643	Retained (old) magnetic foreign body in lens bilateral
H44.741	Retained (nonmagnetic) (old) foreign body in posterior wall of globe right eye
H44.742	Retained (nonmagnetic) (old) foreign body in posterior wall of globe left eye
H44.743	Retained (nonmagnetic) (old) foreign body in posterior wall of globe bilateral
H46.01	Optic papillitis, right eye
H46.02	Optic papillitis, left eye
H46.03	Optic papillitis, bilateral
H46.11	Retrobulbar neuritis right eye
H46.12	Retrobulbar neuritis left eye
H46.13	Retrobulbar neuritis bilateral
H46.2	Nutritional optic neuropathy
H46.3	Toxic optic neuropathy
H47.011	Ischemic optic neuropathy, right eye
H47.012	Ischemic optic neuropathy, left eye
H47.013	Ischemic optic neuropathy, bilateral
H47.021	Hemorrhage in optic nerve sheath right eye
H47.022	Hemorrhage in optic nerve sheath left eye
H47.023	Hemorrhage in optic nerve sheath bilateral
H47.031	Optic nerve hypoplasia right eye
H47.032	Optic nerve hypoplasia left eye
H47.033	Optic nerve hypoplasia bilateral
H47.141	Foster-Kennedy syndrome right eye

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 29 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

H47.142	Foster-Kennedy syndrome left eye
H47.143	Foster-Kennedy syndrome bilateral
H47.22	Hereditary optic atrophy
H47.311	Coloboma of optic disc, right eye
H47.312	Coloboma of optic disc, left eye
H47.313	Coloboma of optic disc, bilateral
H47.321	Drusen of optic disc, right eye
H47.322	Drusen of optic disc, left eye
H47.323	Drusen of optic disc, bilateral
H47.331	Pseudopapilledema of optic disc, right eye
H47.332	Pseudopapilledema of optic disc, left eye
H47.333	Pseudopapilledema of optic disc, bilateral
H53.131	Sudden vision loss right eye
H53.132	Sudden vision loss left eye
H53.133	Sudden vision loss bilateral
H59.031	Cystoid macular edema following cataract surgery, right eye
H59.032	Cystoid macular edema following cataract surgery, left eye
H59.033	Cystoid macular edema following cataract surgery, bilateral
R94.111	Abnormal electroretinogram (ERG)

**State/Payor Specific Coverage**

<b>State</b>	<b>Coverage limitations</b>
Texas Medicaid	Envolve Vision provides reimbursement for this procedure in accordance with Texas state Medicaid guidelines.

**REVIEW/REVISION LOG**

<b>Notes</b>	<b>Date</b>
Annual review	12/2018
Revised definition to indicate bilateral procedure.	07/2018
Update diagnoses as medical indications; update references	01/2018
Addition of diagnoses as medical indications.	10/2017

*These are Confidential and Proprietary materials of Envolve Vision Benefits, Inc. (Envolve Vision), which should not be reproduced in any manner or shared with any third party without the prior written consent of Envolve Vision.*

**ENVOLVE VISION BENEFITS, INC.  
INCLUDING ALL ASSOCIATED SUBSIDIARIES  
CLINICAL POLICY AND PROCEDURE**

<b>DEPARTMENT: Utilization Management</b>	<b>DOCUMENT NAME: Fluorescein Angiography</b>
<b>PAGE: 30 of 30</b>	<b>REFERENCE NUMBER: OC.UM.CP.0028</b>
<b>EFFECTIVE DATE: 01/01/2018</b>	<b>REPLACES DOCUMENT: 178-UM-R7, 3032-MM-R4</b>
<b>RETIRED:</b>	<b>REVIEWED: 10/11/2018</b>
<b>SPECIALIST REVIEW: Yes</b>	<b>REVISED: 6/1/2018</b>
<b>PRODUCT TYPE: All</b>	<b>COMMITTEE APPROVAL: 12/05/2018</b>

Remove unspecified diagnoses from medical indications, update diagnoses based on ICD-10 update and remove Attachment A.	10/2016
Update medical indications	05/2016
Update medical indications, update diagnoses to ICD-10, rebrand to new corporate name	12/2015
Revised documentation requirements; updated diagnoses for medical necessity; addition of Attachment A with ICD9/ICD10 code crosswalk	12/2014
Update of diagnoses and references	12/2013
Clarification of frequency limitations to twice per year	04/2013